Harrington Investments INC Has $2.40 Million Position in Novo Nordisk A/S (NYSE:NVO)

Harrington Investments INC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 0.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,738 shares of the company’s stock after selling 127 shares during the quarter. Novo Nordisk A/S comprises 1.7% of Harrington Investments INC’s investment portfolio, making the stock its 24th largest holding. Harrington Investments INC’s holdings in Novo Nordisk A/S were worth $2,401,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Perigon Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 3.2% during the third quarter. Perigon Wealth Management LLC now owns 2,603 shares of the company’s stock worth $259,000 after buying an additional 80 shares during the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Novo Nordisk A/S by 9.8% during the third quarter. SRS Capital Advisors Inc. now owns 985 shares of the company’s stock worth $98,000 after buying an additional 88 shares during the last quarter. RFG Advisory LLC lifted its holdings in shares of Novo Nordisk A/S by 2.6% during the third quarter. RFG Advisory LLC now owns 3,681 shares of the company’s stock worth $423,000 after buying an additional 92 shares during the last quarter. Kolinsky Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 2.6% during the third quarter. Kolinsky Wealth Management LLC now owns 3,647 shares of the company’s stock worth $363,000 after buying an additional 94 shares during the last quarter. Finally, Csenge Advisory Group lifted its holdings in shares of Novo Nordisk A/S by 3.9% during the third quarter. Csenge Advisory Group now owns 2,542 shares of the company’s stock worth $253,000 after buying an additional 95 shares during the last quarter. 6.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the subject of a number of research analyst reports. Cowen upped their price target on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. StockNews.com assumed coverage on Novo Nordisk A/S in a research report on Thursday. They set a “strong-buy” rating on the stock. JPMorgan Chase & Co. boosted their price objective on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an “overweight” rating in a research report on Tuesday, January 3rd. Finally, Cowen boosted their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $697.78.

Novo Nordisk A/S Price Performance

NYSE:NVO traded up $0.55 during trading hours on Friday, reaching $139.44. The company had a trading volume of 1,727,274 shares, compared to its average volume of 1,292,450. The stock has a 50-day moving average of $139.97 and a two-hundred day moving average of $123.57. Novo Nordisk A/S has a one year low of $95.02 and a one year high of $145.94. The firm has a market capitalization of $315.55 billion, a PE ratio of 40.18, a PEG ratio of 1.47 and a beta of 0.47. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.29.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Shareholders of record on Monday, March 27th will be given a $1.1887 dividend. This represents a yield of 0.8%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. The ex-dividend date is Friday, March 24th. Novo Nordisk A/S’s dividend payout ratio is 23.34%.

About Novo Nordisk A/S

(Get Rating)

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.